drugset
drugset / Trial / NCT03852459

Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS

NCT03852459 ↗

Phase 2 Completed 251 enrolled Aponia Laboratories, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 2 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel 5%

Timeline

Start
2018-01-12
Primary completion
2019-04-04
Completion
2019-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexibuprofen Small molecule 5 % Topical

Indications

No indication recorded.